Entero Therapeutics, Inc. Announces Corporate Name Change to GridAI Technologies Corp. and New Ticker Symbol "GRDX"
Entero Therapeutics (NASDAQ:ENTO) will change its name to GridAI Technologies Corp. and its ticker to GRDX, effective at 12:01 AM/ET on December 1, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Entero Therapeutics (NASDAQ:ENTO) will change its name to GridAI Technologies Corp. and its ticker to GRDX, effective at 12:01 AM/ET on December 1, 2025. The change follows the Company's acquisition of 100% of GRID AI Corp, a grid-edge AI software and controls platform for utilities, retail energy providers, and large power users. The Company's common stock will begin trading on the Nasdaq Capital Market under the new name and symbol on December 1, 2025. The company said the name and ticker changes do not alter its legal structure, operations, or financial reporting, and shareholders are not required to take any action.
Positive
- Acquired 100% of GRID AI Corp
- Name change effective 12:01 ET, Dec 1, 2025
- Ticker GRDX begins trading on Nasdaq Dec 1, 2025
Negative
- None.
Details
News Market Reaction – ENTO
On Nov 28, the day this news came out, ENTO closed 5.28% above the previous close.
Data tracked by StockTitan Argus for the Nov 28 session.
Key Figures
- Acquired ownership
- 100%
- Ownership of GRID AI Corp following acquisition
- Price change
- 5.28%
- 24h move prior to publication on Nov 28, 2025
- Current price
- $2.99
- Last close before name and ticker change news
- 52-week range
- $0.9693–$5.84
- Low and high over the last 52 weeks
- Relative volume
- 6.96x
- Today’s volume vs 20-day average
Historical Context
-
Corporate rebrand to GridAI Technologies and new Nasdaq ticker GRDX.
-
LOI with hyperscaler AI data-center developer outlining multi-year revenue ramp.
-
Plans to appoint U.S. leadership to drive AI infrastructure expansion strategy.
-
LOI to integrate LV Grid team and IP into Grid AI for hyperscaler market.
-
Oct 30
GridAI acquisition
- 24h Move
- -0.7%
Acquisition of GRID AI shifting focus from biotech to grid-edge AI orchestration.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
distributed energy resources technical
battery energy storage systems technical
machine learning technical
edge analytics technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOCA RATON, FL / ACCESS Newswire / November 28, 2025 / Entero Therapeutics, Inc. (NASDAQ:ENTO) (the "Company") today announced that it will change its name to GridAI Technologies Corp., effective at 12:01 Eastern Time on Monday, December 1, 2025. The name change closely aligns the Company's business following its acquisition of
"This marks the beginning of a new chapter for the business," said Jason Sawyer, Interim Chief Executive Officer of GridAI Technologies Corp. "Our mission is to enhance grid-edge intelligence using AI, machine learning and edge analytics by orchestrating supply and demand in real time, creating a more reliable, resilient, and transactive grid -now supported with our public-company platform - and this name change reflects that commitment."
The name and future ticker change do not affect the Company's legal structure, business operations, or existing financial reporting obligations. Shareholders are not required to take any action in connection with the change.
Further updates will be provided via regular press releases and regulatory filings.
About Entero Therapeutics, Inc. (NASDAQ:ENTO)
Entero Therapeutics, Inc. is a publicly listed company on Nasdaq. The Company is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company's programs address significant unmet needs in GI health and comprise development of Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. Following completion of the GRID AI acquisition, the Company intends to continue these prior operations and to also operate GRID AI as a wholly owned subsidiary and pursue opportunities at the intersection of AI and energy infrastructure.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding strategic benefits of the acquisition, market opportunities, product capabilities, stockholder approval of the transaction, Nasdaq's approval of an initial listing application, if any, and future operating results. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. Important factors include, among others, our business strategy; the risk that regulatory or third-party approvals are delayed or not obtained; integration challenges; market adoption; competitive dynamics; macroeconomic and energy-market conditions; and other risks detailed from time to time in the Company's SEC filings. The Company undertakes no obligation to update forward-looking statements.
Investor & Media Contacts:
Entero Investor Relations
investors@enterothera.com
SOURCE: Entero Therapeutics, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.